English
简体中文
Total: £ 56.28
Published Date: 2025-11-05 | Pages: 120 | Tables: 128 | Medical Care
The global Microbial CDMO Service market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
From a downstream perspective, SMBs accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Microbial CDMO Service leading manufacturers including Lonza, AGC Biologics, FUJIFILM Diosynth Biotechnologies, Laurus Bio, BOC Sciences, AbbVie, Cytovance Biologics, ADL Biopharma, EUROAPI, KBI Biopharma, etc., dominate supply; the top five capture approximately % of global revenue, with Lonza leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Microbial CDMO Service market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Lonza
AGC Biologics
FUJIFILM Diosynth Biotechnologies
Laurus Bio
BOC Sciences
AbbVie
Cytovance Biologics
ADL Biopharma
EUROAPI
KBI Biopharma
Segment by Type
Fermentation Scale-Up
cGMP Manufacturing
Other
Segment by Application
SMBs
Large Companies
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Microbial CDMO Service study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to Microbial CDMO Service: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Microbial CDMO Service Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Fermentation Scale-Up
1.2.3 cGMP Manufacturing
1.2.4 Other
1.3 Market Segmentation by Application
1.3.1 Global Microbial CDMO Service Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 SMBs
1.3.3 Large Companies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Microbial CDMO Service Revenue Estimates and Forecasts 2020-2031
2.2 Global Microbial CDMO Service Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Microbial CDMO Service Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Microbial CDMO Service Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Fermentation Scale-Up Market Size by Players
3.3.2 cGMP Manufacturing Market Size by Players
3.3.3 Other Market Size by Players
3.4 Global Microbial CDMO Service Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Microbial CDMO Service Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Microbial CDMO Service Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Microbial CDMO Service Market Size by Type (2020-2031)
6.4 North America Microbial CDMO Service Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Microbial CDMO Service Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Microbial CDMO Service Market Size by Type (2020-2031)
7.4 Europe Microbial CDMO Service Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Microbial CDMO Service Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Microbial CDMO Service Market Size by Type (2020-2031)
8.4 Asia-Pacific Microbial CDMO Service Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Microbial CDMO Service Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Microbial CDMO Service Market Size by Type (2020-2031)
9.4 Central and South America Microbial CDMO Service Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Microbial CDMO Service Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Microbial CDMO Service Market Size by Type (2020-2031)
10.4 Middle East and Africa Microbial CDMO Service Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Microbial CDMO Service Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Lonza
11.1.1 Lonza Corporation Information
11.1.2 Lonza Business Overview
11.1.3 Lonza Microbial CDMO Service Product Features and Attributes
11.1.4 Lonza Microbial CDMO Service Revenue and Gross Margin (2020-2025)
11.1.5 Lonza Microbial CDMO Service Revenue by Product in 2024
11.1.6 Lonza Microbial CDMO Service Revenue by Application in 2024
11.1.7 Lonza Microbial CDMO Service Revenue by Geographic Area in 2024
11.1.8 Lonza Microbial CDMO Service SWOT Analysis
11.1.9 Lonza Recent Developments
11.2 AGC Biologics
11.2.1 AGC Biologics Corporation Information
11.2.2 AGC Biologics Business Overview
11.2.3 AGC Biologics Microbial CDMO Service Product Features and Attributes
11.2.4 AGC Biologics Microbial CDMO Service Revenue and Gross Margin (2020-2025)
11.2.5 AGC Biologics Microbial CDMO Service Revenue by Product in 2024
11.2.6 AGC Biologics Microbial CDMO Service Revenue by Application in 2024
11.2.7 AGC Biologics Microbial CDMO Service Revenue by Geographic Area in 2024
11.2.8 AGC Biologics Microbial CDMO Service SWOT Analysis
11.2.9 AGC Biologics Recent Developments
11.3 FUJIFILM Diosynth Biotechnologies
11.3.1 FUJIFILM Diosynth Biotechnologies Corporation Information
11.3.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.3.3 FUJIFILM Diosynth Biotechnologies Microbial CDMO Service Product Features and Attributes
11.3.4 FUJIFILM Diosynth Biotechnologies Microbial CDMO Service Revenue and Gross Margin (2020-2025)
11.3.5 FUJIFILM Diosynth Biotechnologies Microbial CDMO Service Revenue by Product in 2024
11.3.6 FUJIFILM Diosynth Biotechnologies Microbial CDMO Service Revenue by Application in 2024
11.3.7 FUJIFILM Diosynth Biotechnologies Microbial CDMO Service Revenue by Geographic Area in 2024
11.3.8 FUJIFILM Diosynth Biotechnologies Microbial CDMO Service SWOT Analysis
11.3.9 FUJIFILM Diosynth Biotechnologies Recent Developments
11.4 Laurus Bio
11.4.1 Laurus Bio Corporation Information
11.4.2 Laurus Bio Business Overview
11.4.3 Laurus Bio Microbial CDMO Service Product Features and Attributes
11.4.4 Laurus Bio Microbial CDMO Service Revenue and Gross Margin (2020-2025)
11.4.5 Laurus Bio Microbial CDMO Service Revenue by Product in 2024
11.4.6 Laurus Bio Microbial CDMO Service Revenue by Application in 2024
11.4.7 Laurus Bio Microbial CDMO Service Revenue by Geographic Area in 2024
11.4.8 Laurus Bio Microbial CDMO Service SWOT Analysis
11.4.9 Laurus Bio Recent Developments
11.5 BOC Sciences
11.5.1 BOC Sciences Corporation Information
11.5.2 BOC Sciences Business Overview
11.5.3 BOC Sciences Microbial CDMO Service Product Features and Attributes
11.5.4 BOC Sciences Microbial CDMO Service Revenue and Gross Margin (2020-2025)
11.5.5 BOC Sciences Microbial CDMO Service Revenue by Product in 2024
11.5.6 BOC Sciences Microbial CDMO Service Revenue by Application in 2024
11.5.7 BOC Sciences Microbial CDMO Service Revenue by Geographic Area in 2024
11.5.8 BOC Sciences Microbial CDMO Service SWOT Analysis
11.5.9 BOC Sciences Recent Developments
11.6 AbbVie
11.6.1 AbbVie Corporation Information
11.6.2 AbbVie Business Overview
11.6.3 AbbVie Microbial CDMO Service Product Features and Attributes
11.6.4 AbbVie Microbial CDMO Service Revenue and Gross Margin (2020-2025)
11.6.5 AbbVie Recent Developments
11.7 Cytovance Biologics
11.7.1 Cytovance Biologics Corporation Information
11.7.2 Cytovance Biologics Business Overview
11.7.3 Cytovance Biologics Microbial CDMO Service Product Features and Attributes
11.7.4 Cytovance Biologics Microbial CDMO Service Revenue and Gross Margin (2020-2025)
11.7.5 Cytovance Biologics Recent Developments
11.8 ADL Biopharma
11.8.1 ADL Biopharma Corporation Information
11.8.2 ADL Biopharma Business Overview
11.8.3 ADL Biopharma Microbial CDMO Service Product Features and Attributes
11.8.4 ADL Biopharma Microbial CDMO Service Revenue and Gross Margin (2020-2025)
11.8.5 ADL Biopharma Recent Developments
11.9 EUROAPI
11.9.1 EUROAPI Corporation Information
11.9.2 EUROAPI Business Overview
11.9.3 EUROAPI Microbial CDMO Service Product Features and Attributes
11.9.4 EUROAPI Microbial CDMO Service Revenue and Gross Margin (2020-2025)
11.9.5 EUROAPI Recent Developments
11.10 KBI Biopharma
11.10.1 KBI Biopharma Corporation Information
11.10.2 KBI Biopharma Business Overview
11.10.3 KBI Biopharma Microbial CDMO Service Product Features and Attributes
11.10.4 KBI Biopharma Microbial CDMO Service Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
12 Microbial CDMO ServiceIndustry Chain Analysis
12.1 Microbial CDMO Service Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Microbial CDMO Service Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Microbial CDMO Service Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Microbial CDMO Service Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Microbial CDMO Service Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Microbial CDMO Service Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Microbial CDMO Service Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Microbial CDMO Service Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Microbial CDMO Service Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Microbial CDMO Service Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Microbial CDMO Service by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Microbial CDMO Service as of 2024)
Table 11. Global Microbial CDMO Service Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Microbial CDMO Service Companies Headquarters
Table 13. Global Microbial CDMO Service Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Microbial CDMO Service Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Microbial CDMO Service Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Microbial CDMO Service Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Microbial CDMO Service Revenue by Application (2026-2031) & (US$ Million)
Table 21. Microbial CDMO Service High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Microbial CDMO Service Growth Accelerators and Market Barriers
Table 25. North America Microbial CDMO Service Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Microbial CDMO Service Growth Accelerators and Market Barriers
Table 27. Europe Microbial CDMO Service Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Microbial CDMO Service Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Microbial CDMO Service Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Microbial CDMO Service Investment Opportunities and Key Challenges
Table 31. Central and South America Microbial CDMO Service Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Microbial CDMO Service Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Microbial CDMO Service Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Lonza Corporation Information
Table 35. Lonza Description and Major Businesses
Table 36. Lonza Product Features and Attributes
Table 37. Lonza Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Lonza Revenue Proportion by Product in 2024
Table 39. Lonza Revenue Proportion by Application in 2024
Table 40. Lonza Revenue Proportion by Geographic Area in 2024
Table 41. Lonza Microbial CDMO Service SWOT Analysis
Table 42. Lonza Recent Developments
Table 43. AGC Biologics Corporation Information
Table 44. AGC Biologics Description and Major Businesses
Table 45. AGC Biologics Product Features and Attributes
Table 46. AGC Biologics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. AGC Biologics Revenue Proportion by Product in 2024
Table 48. AGC Biologics Revenue Proportion by Application in 2024
Table 49. AGC Biologics Revenue Proportion by Geographic Area in 2024
Table 50. AGC Biologics Microbial CDMO Service SWOT Analysis
Table 51. AGC Biologics Recent Developments
Table 52. FUJIFILM Diosynth Biotechnologies Corporation Information
Table 53. FUJIFILM Diosynth Biotechnologies Description and Major Businesses
Table 54. FUJIFILM Diosynth Biotechnologies Product Features and Attributes
Table 55. FUJIFILM Diosynth Biotechnologies Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. FUJIFILM Diosynth Biotechnologies Revenue Proportion by Product in 2024
Table 57. FUJIFILM Diosynth Biotechnologies Revenue Proportion by Application in 2024
Table 58. FUJIFILM Diosynth Biotechnologies Revenue Proportion by Geographic Area in 2024
Table 59. FUJIFILM Diosynth Biotechnologies Microbial CDMO Service SWOT Analysis
Table 60. FUJIFILM Diosynth Biotechnologies Recent Developments
Table 61. Laurus Bio Corporation Information
Table 62. Laurus Bio Description and Major Businesses
Table 63. Laurus Bio Product Features and Attributes
Table 64. Laurus Bio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Laurus Bio Revenue Proportion by Product in 2024
Table 66. Laurus Bio Revenue Proportion by Application in 2024
Table 67. Laurus Bio Revenue Proportion by Geographic Area in 2024
Table 68. Laurus Bio Microbial CDMO Service SWOT Analysis
Table 69. Laurus Bio Recent Developments
Table 70. BOC Sciences Corporation Information
Table 71. BOC Sciences Description and Major Businesses
Table 72. BOC Sciences Product Features and Attributes
Table 73. BOC Sciences Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. BOC Sciences Revenue Proportion by Product in 2024
Table 75. BOC Sciences Revenue Proportion by Application in 2024
Table 76. BOC Sciences Revenue Proportion by Geographic Area in 2024
Table 77. BOC Sciences Microbial CDMO Service SWOT Analysis
Table 78. BOC Sciences Recent Developments
Table 79. AbbVie Corporation Information
Table 80. AbbVie Description and Major Businesses
Table 81. AbbVie Product Features and Attributes
Table 82. AbbVie Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. AbbVie Recent Developments
Table 84. Cytovance Biologics Corporation Information
Table 85. Cytovance Biologics Description and Major Businesses
Table 86. Cytovance Biologics Product Features and Attributes
Table 87. Cytovance Biologics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Cytovance Biologics Recent Developments
Table 89. ADL Biopharma Corporation Information
Table 90. ADL Biopharma Description and Major Businesses
Table 91. ADL Biopharma Product Features and Attributes
Table 92. ADL Biopharma Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. ADL Biopharma Recent Developments
Table 94. EUROAPI Corporation Information
Table 95. EUROAPI Description and Major Businesses
Table 96. EUROAPI Product Features and Attributes
Table 97. EUROAPI Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. EUROAPI Recent Developments
Table 99. KBI Biopharma Corporation Information
Table 100. KBI Biopharma Description and Major Businesses
Table 101. KBI Biopharma Product Features and Attributes
Table 102. KBI Biopharma Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. KBI Biopharma Recent Developments
Table 104. Raw Materials Key Suppliers
Table 105. Distributors List
Table 106. Market Trends and Market Evolution
Table 107. Market Drivers and Opportunities
Table 108. Market Challenges, Risks, and Restraints
Table 109. Research Programs/Design for This Report
Table 110. Key Data Information from Secondary Sources
Table 111. Key Data Information from Primary Sources
List of Figures
Figure 1. Microbial CDMO Service Product Picture
Figure 2. Global Microbial CDMO Service Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Fermentation Scale-Up Product Picture
Figure 4. cGMP Manufacturing Product Picture
Figure 5. Other Product Picture
Figure 6. Global Microbial CDMO Service Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. SMBs
Figure 8. Large Companies
Figure 9. Microbial CDMO Service Report Years Considered
Figure 10. Global Microbial CDMO Service Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Microbial CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 12. Global Microbial CDMO Service Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global Microbial CDMO Service Revenue Market Share by Region (2020-2031)
Figure 14. Global Microbial CDMO Service Revenue Market Share Ranking (2024)
Figure 15. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 16. Fermentation Scale-Up Revenue Market Share by Player in 2024
Figure 17. cGMP Manufacturing Revenue Market Share by Player in 2024
Figure 18. Other Revenue Market Share by Player in 2024
Figure 19. Global Microbial CDMO Service Revenue Market Share by Type (2020-2031)
Figure 20. Global Microbial CDMO Service Revenue Market Share by Application (2020-2031)
Figure 21. North America Microbial CDMO Service Revenue YoY (2020-2031) & (US$ Million)
Figure 22. North America Top 5 Players Microbial CDMO Service Revenue (US$ Million) in 2024
Figure 23. North America Microbial CDMO Service Revenue (US$ Million) by Type (2020 - 2031)
Figure 24. North America Microbial CDMO Service Revenue (US$ Million) by Application (2020-2031)
Figure 25. US Microbial CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 26. Canada Microbial CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 27. Mexico Microbial CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 28. Europe Microbial CDMO Service Revenue YoY (2020-2031) & (US$ Million)
Figure 29. Europe Top 5 Players Microbial CDMO Service Revenue (US$ Million) in 2024
Figure 30. Europe Microbial CDMO Service Revenue (US$ Million) by Type (2020-2031)
Figure 31. Europe Microbial CDMO Service Revenue (US$ Million) by Application (2020-2031)
Figure 32. Germany Microbial CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 33. France Microbial CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 34. U.K. Microbial CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 35. Italy Microbial CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 36. Russia Microbial CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Microbial CDMO Service Revenue YoY (2020-2031) & (US$ Million)
Figure 38. Asia-Pacific Top 8 Players Microbial CDMO Service Revenue (US$ Million) in 2024
Figure 39. Asia-Pacific Microbial CDMO Service Revenue (US$ Million) by Type (2020-2031)
Figure 40. Asia-Pacific Microbial CDMO Service Revenue (US$ Million) by Application (2020-2031)
Figure 41. Indonesia Microbial CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 42. Japan Microbial CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 43. South Korea Microbial CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 44. Australia Microbial CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 45. India Microbial CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 46. Indonesia Microbial CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 47. Vietnam Microbial CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 48. Malaysia Microbial CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 49. Philippines Microbial CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 50. Singapore Microbial CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 51. Central and South America Microbial CDMO Service Revenue YoY (2020-2031) & (US$ Million)
Figure 52. Central and South America Top 5 Players Microbial CDMO Service Revenue (US$ Million) in 2024
Figure 53. Central and South America Microbial CDMO Service Revenue (US$ Million) by Type (2020-2031)
Figure 54. Central and South America Microbial CDMO Service Revenue (US$ Million) by Application (2020-2031)
Figure 55. Brazil Microbial CDMO Service Revenue (2020-2025) & (US$ Million)
Figure 56. Argentina Microbial CDMO Service Revenue (2020-2025) & (US$ Million)
Figure 57. Middle East and Africa Microbial CDMO Service Revenue YoY (2020-2031) & (US$ Million)
Figure 58. Middle East and Africa Top 5 Players Microbial CDMO Service Revenue (US$ Million) in 2024
Figure 59. South America Microbial CDMO Service Revenue (US$ Million) by Type (2020-2031)
Figure 60. Middle East and Africa Microbial CDMO Service Revenue (US$ Million) by Application (2020-2031)
Figure 61. GCC Countries Microbial CDMO Service Revenue (2020-2025) & (US$ Million)
Figure 62. Israel Microbial CDMO Service Revenue (2020-2025) & (US$ Million)
Figure 63. Egypt Microbial CDMO Service Revenue (2020-2025) & (US$ Million)
Figure 64. South Africa Microbial CDMO Service Revenue (2020-2025) & (US$ Million)
Figure 65. Microbial CDMO Service Industry Chain Mapping
Figure 66. Channels of Distribution (Direct Vs Distribution)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
